AmCham China’s Healthcare Industry Group: Facilitating Progress & Connection in China’s Healthcare Industry

Explore the dynamic journey of AmCham China’s Healthcare Industry Group as it drives vital exchanges and collaboration between the US and China in the healthcare sector. Through initiatives like the US-China Health Cooperation Program, the group fosters impactful partnerships, amplifying accessibility and innovation in healthcare services. Join us as the Quarterly explores the Group’s 2023 visits and outlines the promising prospects for 2024.

AmCham China’s Healthcare Industry Group, comprising over 130 member companies across biopharmaceuticals, medical devices, and healthcare services sectors, stands as a linchpin in fostering exchanges between the US and China in healthcare. Aligned with the US-China Healthcare Cooperation Program (HCP) since 2011, the Group endeavors to deepen collaboration between the two nations across crucial domains such as public health, policy research, and technology. Through established connections with relevant government agencies and healthcare departments, the Group spearheads projects and initiatives aimed at bolstering healthcare accessibility and long-term bilateral cooperation. Discover the Group’s impactful initiatives from 2023 and get a sneak peek into the planned visits for the upcoming year, showcasing ongoing efforts to drive innovation and progress in China’s dynamic healthcare landscape.

HCP 2023 Delegation Visits

Photo courtesy of AmCham China

HCP 2024 Delegation Visits

Photo courtesy of AmCham China


This article is from the AmCham China Quarterly Magazine (Issue 1, 2024). To access the entire publication for free, sign up on our member portal here.